Drug Name: Rivfloza
Active Ingredient: nedosiran
Indications: To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function
Approval Date: 9/29/2023
Company: Dicerna Pharmaceuticals, Inc. (a Novo Nordisk company)
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf